Completed NCT03376763
This study is completed in South Korea. It focuses on schizophrenia.
Multiple locations, including Gongju Schizophrenia Drug i A study involving a medication or substance. From 19 Years to 64 Years
Countries South Korea
Sponsor Korea Otsuka Pharmaceutical Co., Ltd.
Condition Schizophrenia Completed NCT00087880
This summary needs review. Please check the official study record and contact the research team for details.
In San Francisco Addiction Drug Over 18 Years
Countries United States
Sponsor National Institute on Drug Abuse (NIDA)
Condition Addiction Completed NCT06011759
This summary needs review. Please check the official study record and contact the research team for details.
In Ann Arbor Suicidality Behavioral
Countries United States
Sponsor VA Office of Research and Development
Condition Suicidality Completed NCT02942979
This summary needs review. Please check the official study record and contact the research team for details.
In Bedford Addiction Other
Countries United States
Sponsor VA Office of Research and Development
Condition Addiction Completed NCT01162239
This summary needs review. Please check the official study record and contact the research team for details.
In San Francisco Addiction Drug Over 18 Years
Countries United States
Sponsor University of California, San Francisco
Condition Addiction Completed NCT05339074
This study exists to understand how ketamine treatment holds up over time after the earliest research stage. Researchers are trying to understand how people respond to ketamine treatment in practice and what may need to be adjusted.
Multiple locations, including Toronto Bipolarity, Depression Drug From 21 Years to 65 Years
Countries Canada
Sponsor Joshua Rosenblat
Condition Bipolarity, Depression Completed NCT01415154
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Chicago Depression Device i A study involving a tool, app, wearable, test, or medical device. From 18 Years to 70 Years
Countries United States
Sponsor Neuronetics
Condition Depression Completed NCT00191035
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Pasadena ADHD Drug From 13 Years to 16 Years
Countries United States
Sponsor Eli Lilly and Company
Condition ADHD Completed NCT01081145
This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.
Multiple locations, including Dothan ADHD Drug From 6 Years to 17 Years
Countries United States, France, Canada, ...
Sponsor Shire
Condition ADHD Completed NCT01888107
This summary needs review. Please check the official study record and contact the research team for details.
Location not clearly listed Schizophrenia Drug Over 18 Years
Countries
Sponsor Janssen-Cilag S.p.A.
Condition Schizophrenia Completed EUCTR 2004-000830-35
This summary needs review. Please check the official study record and contact the research team for details.
In Italy Schizophrenia Other
Countries Italy
Sponsor JANSSEN-CILAG
Condition Schizophrenia Terminated NCT00203385
This summary needs review. Please check the official study record and contact the research team for details.
In Tuscaloosa PTSD Drug Over 19 Years
Countries United States
Sponsor Tuscaloosa Research & Education Advancement Corporation
Condition PTSD